Shanghai Pharmaceuticals

Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), China’s pharmaceutical distribution leader, announced a licensing agreement with...

Others

Shanghai Pharmaceuticals and Henlius Forge Strategic Alliance – Hospital Market Expansion and Global Commercial Collaboration Targeted

Fineline Cube Mar 17, 2026

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH; HKG: 2607, SHA: 601607) and Henlius (HKG: 2696) announced...

Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced plans to transfer its 30% equity...

Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026

Shanghai MediTrust Health Technology Group Co., Ltd. (a subsidiary of Shanghai Pharmaceuticals) announced a comprehensive...

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026

Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that its B023 cell...

Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026

Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical...

Company Drug

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Fineline Cube Dec 11, 2025

Shanghai Pharmaceuticals Holding Co., Ltd. (SHA: 601607) announced that the National Medical Products Administration (NMPA)...

Company Deals

Shanghai Pharma X842 Deal Termination with Sinorda

Fineline Cube Dec 8, 2025

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced the termination of its...

Company Deals

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Fineline Cube Nov 8, 2025

In a high‑profile signing at the 8th China International Import Expo (CIIE), Eisai China (TYO:...

Company

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge

Fineline Cube Aug 29, 2025

Shanghai Pharmaceutical Holding Co., Ltd. (SHA: 601607, HKG: 2607) on Aug. 28, 2025 announced its...

Company Deals

Shanghai Pharmaceuticals and Baxter China Forge Strategic Partnership for Anesthesia Products

Fineline Cube Aug 15, 2025

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, HKG: 2607, SHA: 601607) announced the signing of a...

Company Drug

Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials

Fineline Cube Jul 30, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) announced that it has received...

Company Deals

Shanghai Pharma and Cutia Therapeutic Collaborate on Codon Biopharma’s Innovative Drug Distribution

Fineline Cube Jul 22, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced the signing of...

Company Deals Digital

Shanghai Pharmaceuticals’ MediTrust Health Files for IPO in Hong Kong Amidst AI-Powered Healthcare Payment Transformation

Fineline Cube Jul 2, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) subsidiary, Shanghai MediTrust Health Technology...

Company Drug

Shanghai Pharmaceuticals Receives Thai FDA Approval for Pregabalin Capsules

Fineline Cube Jun 20, 2025

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SPH, HKG: 2607, SHA: 601607) announced that it has...

Company Deals

Shandong Boan Partners with Shanghai Pharma for BA5101 Diabetes Drug

Fineline Cube Jun 12, 2025

China-based Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced a strategic collaboration with Shanghai Pharmaceuticals...

Company Deals

Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products

Fineline Cube Jun 5, 2025

China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...

Company Deals

Shanghai Pharma Collaborates with Novartis China on Ophthalmic Products

Fineline Cube May 27, 2025

China’s Shanghai Pharmaceuticals Holding Ltd (SPH, HKG: 2607, SHA: 601607) announced this week a strategic...

Company Deals

Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China

Fineline Cube Apr 30, 2025

France-based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the signing of a cooperation agreement with...

Company

Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline

Fineline Cube Apr 29, 2025

China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) released its Q1 2025 financial results, showing...

Shanghai Pharmaceuticals

Shanghai Pharmaceuticals Licenses MCB-166 Antidepressant from SJTU – Novel Mechanism Drug Candidate Targets Mental Health Pipeline

Shanghai Pharmaceuticals and Henlius Forge Strategic Alliance – Hospital Market Expansion and Global Commercial Collaboration Targeted

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

MediTrust Mabwell Insurance Ecosystem Partnership

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Shanghai Pharma X842 Deal Termination with Sinorda

Eisai China Partners with Shanghai Pharmaceuticals Holding – Focus on Oncology, Neuroscience and Sleep Disorders

Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge

Shanghai Pharmaceuticals and Baxter China Forge Strategic Partnership for Anesthesia Products

Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials

Shanghai Pharma and Cutia Therapeutic Collaborate on Codon Biopharma’s Innovative Drug Distribution

Shanghai Pharmaceuticals’ MediTrust Health Files for IPO in Hong Kong Amidst AI-Powered Healthcare Payment Transformation

Shanghai Pharmaceuticals Receives Thai FDA Approval for Pregabalin Capsules

Shandong Boan Partners with Shanghai Pharma for BA5101 Diabetes Drug

Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products

Shanghai Pharma Collaborates with Novartis China on Ophthalmic Products

Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China

Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline

You Missed

Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion

Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer

Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal

Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen